Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a fresh disclosure attached to it.

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 41,000 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00. Following the completion of the sale, the chief executive officer directly owned 602,209 shares

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 45,000 shares of the company's stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00. Following the sale, the chief executive officer owned 643,209 shares of the company's

BioNTech said on Monday ​that a late-stage ‌trial showed its drug candidate gotistobart ​led to a ​clinically meaningful overall survival ⁠benefit in ​a certain form of ​lung cancer compared with standard treatment.

MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial (NCT05671510) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease progressed on prior immunotherapy and chemotherapy. Gotistobart is an investigational CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells (“Tregs”) within the tumor microenvironment and restore anti-tumor immune activity.

BioNTech and Moderna are no longer generating significant revenue from their coronavirus vaccines. Both have attractive pipelines that could lead to important new approvals over the next few years.

BioNTech has not performed well in recent years, as its COVID-19 portfolio has struggled. However, the company's mRNA platform is looking increasingly valuable.

BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.

On CNBC's “Halftime Report Final Trades,” Kevin Simpson, founder and CEO of Capital Wealth Planning, picked Take-Two Interactive Software, Inc. (NASDAQ:TTWO).

BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. BNTX's next-gen anti-CTLA-4 gotistobart and PD-L1xVEGF-A bispecific antibody pumitamig have multiple pivotal trial catalysts, with key data readouts expected at WCLC 2026. COMIRNATY's XFG variant expansion provides near-term revenue, but COVID-19 vaccine sales face competitive and demand headwinds, reflected in lowered 2026 guidance.